322 related articles for article (PubMed ID: 9193351)
1. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience.
Krischer JP; Epstein S; Cuthbertson DD; Goorin AM; Epstein ML; Lipshultz SE
J Clin Oncol; 1997 Apr; 15(4):1544-52. PubMed ID: 9193351
[TBL] [Abstract][Full Text] [Related]
2. Cardiac toxicity after anthracycline chemotherapy in childhood.
Iarussi D; Indolfi P; Galderisi M; Bossone E
Herz; 2000 Nov; 25(7):676-88. PubMed ID: 11141677
[TBL] [Abstract][Full Text] [Related]
3. Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study.
van Dalen EC; van der Pal HJ; Kok WE; Caron HN; Kremer LC
Eur J Cancer; 2006 Dec; 42(18):3191-8. PubMed ID: 16987655
[TBL] [Abstract][Full Text] [Related]
4. Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.
Nysom K; Holm K; Lipsitz SR; Mone SM; Colan SD; Orav EJ; Sallan SE; Olsen JH; Hertz H; Jacobsen JR; Lipshultz SE
J Clin Oncol; 1998 Feb; 16(2):545-50. PubMed ID: 9469339
[TBL] [Abstract][Full Text] [Related]
5. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study.
Kremer LC; van Dalen EC; Offringa M; Ottenkamp J; Voûte PA
J Clin Oncol; 2001 Jan; 19(1):191-6. PubMed ID: 11134212
[TBL] [Abstract][Full Text] [Related]
6. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity.
Sorensen K; Levitt G; Bull C; Chessells J; Sullivan I
J Clin Oncol; 1997 Jan; 15(1):61-8. PubMed ID: 8996125
[TBL] [Abstract][Full Text] [Related]
7. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
8. Anthracycline-induced cardiotoxicity in patients with paediatric bone sarcoma and soft tissue sarcoma.
Bini I; Asaftei SD; Riggi C; Tirtei E; Manicone R; Biasin E; Basso ME; Agnoletti G; Fagioli F
Cardiol Young; 2017 Nov; 27(9):1815-1822. PubMed ID: 28780919
[TBL] [Abstract][Full Text] [Related]
9. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
Ryberg M; Nielsen D; Cortese G; Nielsen G; Skovsgaard T; Andersen PK
J Natl Cancer Inst; 2008 Aug; 100(15):1058-67. PubMed ID: 18664656
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors of Daunorubicine Induced Early Cardiotoxicity in Childhood Acute Lymphoblastic Leukemia: A Retrospective Study.
Samosir SM; Utamayasa IKA; Andarsini MR; Rahman MA; Ontoseno T; Hidayat T; Ugrasena IDG; Larasati MCS; Cahyadi A
Asian Pac J Cancer Prev; 2021 May; 22(5):1407-1412. PubMed ID: 34048168
[TBL] [Abstract][Full Text] [Related]
11. Cardiac complications in childhood cancer survivors treated with anthracyclines.
Franco VI; Lipshultz SE
Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
[TBL] [Abstract][Full Text] [Related]
12. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.
Cardinale D; Colombo A; Bacchiani G; Tedeschi I; Meroni CA; Veglia F; Civelli M; Lamantia G; Colombo N; Curigliano G; Fiorentini C; Cipolla CM
Circulation; 2015 Jun; 131(22):1981-8. PubMed ID: 25948538
[TBL] [Abstract][Full Text] [Related]
13. N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children.
Ekstein S; Nir A; Rein AJ; Perles Z; Bar-Oz B; Salpeter L; Algur N; Weintraub M
J Pediatr Hematol Oncol; 2007 Jul; 29(7):440-4. PubMed ID: 17609620
[TBL] [Abstract][Full Text] [Related]
14. [Cardiotoxicity of anthracycline].
Wojtukiewicz MZ; Omyła J; Kozłowski L; Szynaka B
Postepy Hig Med Dosw; 2000; 54(4):467-85. PubMed ID: 11016267
[TBL] [Abstract][Full Text] [Related]
15. Anthracycline induced cardiac toxicity in pediatric Ewing sarcoma: a longitudinal study.
Brown TR; Vijarnsorn C; Potts J; Milner R; Sandor GG; Fryer C
Pediatr Blood Cancer; 2013 May; 60(5):842-8. PubMed ID: 23382019
[TBL] [Abstract][Full Text] [Related]
16. Epidemiology of anthracycline cardiotoxicity in children and adults.
Grenier MA; Lipshultz SE
Semin Oncol; 1998 Aug; 25(4 Suppl 10):72-85. PubMed ID: 9768828
[TBL] [Abstract][Full Text] [Related]
17. The value of echocardiography versus cardiac troponin I levels in the early detection of anthracycline cardiotoxicity in childhood acute leukemia: prospective evaluation of a 7-year-long clinical follow-up.
Oztarhan K; Guler S; Aktas B; Arslan M; Salcioglu Z; Aydogan G
Pediatr Hematol Oncol; 2011 Aug; 28(5):380-94. PubMed ID: 21699467
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Echocardiographic Detection of Treatment-Related Cardiac Dysfunction in Adult Survivors of Childhood Cancer: Results From the St. Jude Lifetime Cohort Study.
Armstrong GT; Joshi VM; Ness KK; Marwick TH; Zhang N; Srivastava D; Griffin BP; Grimm RA; Thomas J; Phelan D; Collier P; Krull KR; Mulrooney DA; Green DM; Hudson MM; Robison LL; Plana JC
J Am Coll Cardiol; 2015 Jun; 65(23):2511-22. PubMed ID: 26065990
[TBL] [Abstract][Full Text] [Related]
19. Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease.
Bu'Lock FA; Gabriel HM; Oakhill A; Mott MG; Martin RP
Br Heart J; 1993 Aug; 70(2):185-8. PubMed ID: 8038032
[TBL] [Abstract][Full Text] [Related]
20. Heart Failure in Relation to Anthracyclines and Other Chemotherapies.
Agunbiade TA; Zaghlol RY; Barac A
Methodist Debakey Cardiovasc J; 2019; 15(4):243-249. PubMed ID: 31988684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
